Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration - Archive ouverte HAL Access content directly
Conference Papers Year :

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

ANNALS OF ONCOLOGY Volume: 30 Supplement: 5 Pages: 867-867 Meeting Abstract: LBA30_PR Published: OCT 2019

(1) , (2) , (3) , (2) , (4) , (5) , (6) , (7) , (2) , , (8) , (9) , , (10) , (11) , (12) , (13)
1
2
3
4
5
6
7
8
9
10
11
12
13
Not file

Dates and versions

inserm-02413130 , version 1 (16-12-2019)

Identifiers

  • HAL Id : inserm-02413130 , version 1

Cite

Julien Taieb, Valérie Taly, Dewi Vernerey, Camille Bourreau, Jaafar Bennouna, et al.. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. 44th Congress of the European-Society-for-Medical-Oncology (ESMO) Location: Barcelona, SPAIN Date: SEP 27-OCT 01, 2019, Sep 2019, Barcelone, France. ⟨inserm-02413130⟩
118 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More